SEC Comment Letter 0000000000-23-012636 to VYNE Therapeutics Inc. (VYNE) (CIK 0001566044) (VYNE)
VYNE Therapeutics Inc. (VYNE) (CIK 0001566044)
Date: Nov. 17, 2023 · CIK: 0001566044 · Accession: 0000000000-23-012636
AI Filing Summary & Sentiment
File numbers found in text: 333-275507
Letter
United States securities and exchange commission logo November 17, 2023 David Domzalski Chief Executive Officer VYNE Therapeutics Inc. 685 Route 202/206 N., Suite 301 Bridgewater, NJ 08807 Re:VYNE Therapeutics Inc. Registration Statement on Form S-3 Filed November 13, 2023 File No. 333-275507 Dear David Domzalski: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Mark Ballantyne, Esq.
Show Raw Text
United States securities and exchange commission logo
November 17, 2023
David Domzalski
Chief Executive Officer
VYNE Therapeutics Inc.
685 Route 202/206 N., Suite 301
Bridgewater, NJ 08807
Re:VYNE Therapeutics Inc.
Registration Statement on Form S-3
Filed November 13, 2023
File No. 333-275507
Dear David Domzalski:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Mark Ballantyne, Esq.